MEDICO LEGAL M A G A Z I N E
MEDICAL REPORTING IN 2017, THE YEAR OF INNOVATION? By Dr David Pearce, Director, Nephos Solutions MedCo has seen little evidence of the mature, fit for purpose Medico-Legal sector that industry has spent so many years portraying to both government and the market in general. Calculated disruption to both randomisation and the accreditation process have failed to achieve the antagonists’ goal of making MedCo last as long the HIP packs did in conveyancing. And there appears to be little retreat in these tactics following the recent belated implementation of the review, with emergency meetings and rumours of calls for refunds for the shell companies, despite three public statements during the summer that none would be given.
8
Sp o n s o re d by:
Whilst I would admit that some aspects of the guidance on the new criteria require clarification, there are significant aspects which support randomisation, fragmentation and appear to level the playing field. Any form of group marketing is clearly banned, but this comes hand in hand with the prevention of Tier 1 companies with shared common ownership from having the same client markets. This clearly prevents double dipping with the same customers. The challenge for progressive MROs in 2017 is to offer instructing parties the ability to work with 4050 MROs in any given year, whilst remaining a fully
